Amerikanische Gesellschaft für Hirudotherapie

Molecular dissection of Na+ binding to thrombin.

Research article published in The Journal of biological chemistry (2004)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungSpeichel-PharmakologiePineda et al. · The Journal of biological chemistry, 2004

Abstract

Na(+) binding near the primary specificity pocket of thrombin promotes the procoagulant, prothrombotic, and signaling functions of the enzyme. The effect is mediated allosterically by a communication between the Na(+) site and regions involved in substrate recognition. Using a panel of 78 Ala mutants of thrombin, we have mapped the allosteric core of residues that are energetically linked to Na(+) binding. These residues are Asp-189, Glu-217, Asp-222, and Tyr-225, all in close proximity to the bound Na(+). Among these residues, Asp-189 shares with Asp-221 the important function of transducing Na(+) binding into enhanced catalytic activity. None of the residues of exosite I, exosite II, or the 60-loop plays a significant role in Na(+) binding and allosteric transduction. X-ray crystal structures of the Na(+)-free (slow) and Na(+)-bound (fast) forms of thrombin, free or bound to the active site inhibitor H-d-Phe-Pro-Arg-chloromethyl-ketone, document the conformational changes induced by Na(+) binding. The slow --> fast transition results in formation of the Arg-187:Asp-222 ion pair, optimal orientation of Asp-189 and Ser-195 for substrate binding, and a significant shift of the side chain of Glu-192 linked to a rearrangement of the network of water molecules that connect the bound Na(+) to Ser-195 in the active site. The changes in the water network and the allosteric core explain the thermodynamic signatures linked to Na(+) binding and the mechanism of thrombin activation by Na(+). The role of the water network uncovered in this study establishes a new paradigm for the allosteric regulation of thrombin and other Na(+)-activated enzymes involved in blood coagulation and the immune response.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAllosteric SiteCrystallography, X-RayHumansIn Vitro TechniquesModels, MolecularMutagenesis, Site-DirectedProtein ConformationRecombinant ProteinsSodiumStatic ElectricityThermodynamicsThrombin

Zusammenfassung

Na(+) binding near the primary specificity pocket of thrombin promotes the procoagulant, prothrombotic, and signaling functions of the enzyme. The effect is mediated allosterically by a communication between the Na(+) site and regions involved in substrate recognition.

Warum dies für die Hirudotherapie relevant ist

This study used a panel of 78 alanine mutants and X-ray crystal structures of Na+-free (slow) and Na+-bound (fast) thrombin forms to map the allosteric core of residues energetically linked to Na+ binding, identifying Asp-189, Glu-217, Asp-222, and Tyr-225 as key components. The findings reveal that the slow-to-fast transition involves formation of the Arg-187:Asp-222 ion pair, optimal orientation of Asp-189 and Ser-195, and a water network connecting bound Na+ to the catalytic Ser-195. The work establishes a new paradigm for allosteric regulation of thrombin and other Na+-activated clotting enzymes. CAVEAT: No hirudin, leech-derived compounds, or hirudotherapy are mentioned in the abstract; this is an in-vitro structural/mutagenesis study with no defensible leech link to ASH's domain.

Zitation

Molecular dissection of Na+ binding to thrombin.

Pineda et al. · The Journal of biological chemistry, 2004

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.